Next Article in Journal
Development, Characterization, and In Vitro Evaluation of Resveratrol-Loaded Poly-(ε-caprolactone) Microcapsules Prepared by Ultrasonic Atomization for Intra-Articular Administration
Next Article in Special Issue
A Snapshot of Transdermal and Topical Drug Delivery Research in Canada
Previous Article in Journal
pH-Responsive i-motif Conjugated Hyaluronic Acid/Polyethylenimine Complexes for Drug Delivery Systems
Previous Article in Special Issue
Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics
Open AccessArticle

Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience

Division of Neurosurgery and Neuro-Oncology, Department of surgery, Faculty of Medicine and Health Science, University of Sherbrooke, Sherbrooke, QC J1H-5N4, Canada
Pharmaceutics 2019, 11(5), 248; https://doi.org/10.3390/pharmaceutics11050248
Received: 8 April 2019 / Revised: 21 May 2019 / Accepted: 22 May 2019 / Published: 27 May 2019
(This article belongs to the Special Issue Drug Delivery Technology Development in Canada)
Drug delivery to the central nervous system (CNS) remains a challenge in neuro-oncology. Despite decades of research in this field, no consensus has emerged as to the best approach to tackle this physiological limitation. Moreover, the relevance of doing so is still sometimes questioned in the community. In this paper, we present our experience with CNS delivery strategies that have been developed in the laboratory and have made their way to the clinic in a continuum of translational research. Using the intra-arterial (IA) route as an avenue to deliver chemotherapeutics in the treatment of brain tumors, complemented by an osmotic breach of the blood-brain barrier (BBB) in specific situations, we have developed over the years a comprehensive research effort on this specialized topic. Looking at pre-clinical work supporting the rationale for this approach, and presenting results discussing the safety of the strategy, as well as results obtained in the treatment of malignant gliomas and primary CNS lymphomas, this paper intends to comprehensively summarize our work in this field. View Full-Text
Keywords: blood-brain barrier; intra-arterial chemotherapy; malignant gliomas; primary central nervous system lymphomas blood-brain barrier; intra-arterial chemotherapy; malignant gliomas; primary central nervous system lymphomas
Show Figures

Figure 1

MDPI and ACS Style

Fortin, D. Drug Delivery Technology to the CNS in the Treatment of Brain Tumors: The Sherbrooke Experience. Pharmaceutics 2019, 11, 248.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop